Article and Video CATEGORIES
With the Thanksgiving holiday in November, the month has become synonymous with gratitude in the U.S. November is also Lung Cancer Awareness Month; an initiative started in 1995 to increase knowledge of the disease.
GRACE decided to combine the two ideas. For the next month, we will post videos, images and blog posts where a patient, caregiver, or doctor highlights a currently- or soon-to-be enrolling clinical trial, a victory against lung cancer, or their gratitude in the realm of lung cancer.
What we want to accomplish is threefold:
- First and foremost, we want more lung cancer patients talking to their doctors about clinical trials. GRACE’s team of faculty will highlight 15 trials that they think are the most exciting.
- Secondly, we want to celebrate the moments of beauty that arise even during some of the toughest days of our lives. We asked doctors, patients, and caregivers to tell us, “In the world of lung cancer, what are you grateful for?”
- Finally, we hope to give patients and caregivers a peek at the softer side of their medical teams. The doctors who participated in this initiative did so out of love, admiration and – yes – gratitude for their patients.
And speaking of gratitude, I’d like to thank the doctors, patients, and caregivers who gave some pretty personal answers for our videos. Thank you to the doctors and researchers who are searching for answers through clinical trials. And thank you to Smart Patients, Celgene, Boehringer-Ingelheim, and Astra Zeneca for their support our gratitude campaign.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…